PURPOSE: Because current approaches to risk classification and treatment stratification for children with neuroblastoma (NB) vary greatly throughout the world, it is difficult to directly compare risk-based clinical trials. The International Neuroblastoma Risk Group (INRG) classification system was developed to establish a consensus approach for pretreatment risk stratification. PATIENTS AND METHODS: The statistical and clinical significance of 13 potential prognostic factors were analyzed in a cohort of 8,800 children diagnosed with NB between 1990 and 2002 from North America and Australia (Children's Oncology Group), Europe (International Society of Pediatric Oncology Europe Neuroblastoma Group and German Pediatric Oncology and Hematology Group), and Japan. Survival tree regression analyses using event-free survival (EFS) as the primary end point were performed to test the prognostic significance of the 13 factors. RESULTS: Stage, age, histologic category, grade of tumor differentiation, the status of the MYCN oncogene, chromosome 11q status, and DNA ploidy were the most highly statistically significant and clinically relevant factors. A new staging system (INRG Staging System) based on clinical criteria and tumor imaging was developed for the INRG Classification System. The optimal age cutoff was determined to be between 15 and 19 months, and 18 months was selected for the classification system. Sixteen pretreatment groups were defined on the basis of clinical criteria and statistically significantly different EFS of the cohort stratified by the INRG criteria. Patients with 5-year EFS more than 85%, more than 75% to < or = 85%, > or = 50% to < or = 75%, or less than 50% were classified as very low risk, low risk, intermediate risk, or high risk, respectively. CONCLUSION: By defining homogenous pretreatment patient cohorts, the INRG classification system will greatly facilitate the comparison of risk-based clinical trials conducted in different regions of the world and the development of international collaborative studies.
PURPOSE: Because current approaches to risk classification and treatment stratification for children with neuroblastoma (NB) vary greatly throughout the world, it is difficult to directly compare risk-based clinical trials. The International Neuroblastoma Risk Group (INRG) classification system was developed to establish a consensus approach for pretreatment risk stratification. PATIENTS AND METHODS: The statistical and clinical significance of 13 potential prognostic factors were analyzed in a cohort of 8,800 children diagnosed with NB between 1990 and 2002 from North America and Australia (Children's Oncology Group), Europe (International Society of Pediatric Oncology Europe Neuroblastoma Group and German Pediatric Oncology and Hematology Group), and Japan. Survival tree regression analyses using event-free survival (EFS) as the primary end point were performed to test the prognostic significance of the 13 factors. RESULTS: Stage, age, histologic category, grade of tumor differentiation, the status of the MYCN oncogene, chromosome 11q status, and DNA ploidy were the most highly statistically significant and clinically relevant factors. A new staging system (INRG Staging System) based on clinical criteria and tumor imaging was developed for the INRG Classification System. The optimal age cutoff was determined to be between 15 and 19 months, and 18 months was selected for the classification system. Sixteen pretreatment groups were defined on the basis of clinical criteria and statistically significantly different EFS of the cohort stratified by the INRG criteria. Patients with 5-year EFS more than 85%, more than 75% to < or = 85%, > or = 50% to < or = 75%, or less than 50% were classified as very low risk, low risk, intermediate risk, or high risk, respectively. CONCLUSION: By defining homogenous pretreatment patient cohorts, the INRG classification system will greatly facilitate the comparison of risk-based clinical trials conducted in different regions of the world and the development of international collaborative studies.
Authors: Edward F Attiyeh; Wendy B London; Yael P Mossé; Qun Wang; Cynthia Winter; Deepa Khazi; Patrick W McGrady; Robert C Seeger; A Thomas Look; Hiroyuki Shimada; Garrett M Brodeur; Susan L Cohn; Katherine K Matthay; John M Maris Journal: N Engl J Med Date: 2005-11-24 Impact factor: 91.245
Authors: Giovanni Cecchetto; Veronique Mosseri; Bruno De Bernardi; Pierre Helardot; Tom Monclair; Elisa Costa; Ernst Horcher; Sylvia Neuenschwander; Paolo Tomà; Antonino Rizzo; Jean Michon; Keith Holmes Journal: J Clin Oncol Date: 2005-11-20 Impact factor: 44.544
Authors: R Ladenstein; I M Ambros; U Pötschger; G Amann; C Urban; F M Fink; K Schmitt; R Jones; M Slociak; F Schilling; J Ritter; F Berthold; H Gadner; P F Ambros Journal: Med Pediatr Oncol Date: 2001-01
Authors: J M Maris; M J Weiss; C Guo; R B Gerbing; D O Stram; P S White; M D Hogarty; E P Sulman; P M Thompson; J N Lukens; K K Matthay; R C Seeger; G M Brodeur Journal: J Clin Oncol Date: 2000-05 Impact factor: 44.544
Authors: Tom Monclair; Garrett M Brodeur; Peter F Ambros; Hervé J Brisse; Giovanni Cecchetto; Keith Holmes; Michio Kaneko; Wendy B London; Katherine K Matthay; Jed G Nuchtern; Dietrich von Schweinitz; Thorsten Simon; Susan L Cohn; Andrew D J Pearson Journal: J Clin Oncol Date: 2008-12-01 Impact factor: 44.544
Authors: Thorsten Simon; Barbara Hero; Gabriele Benz-Bohm; Dietrich von Schweinitz; Frank Berthold Journal: Pediatr Blood Cancer Date: 2008-05 Impact factor: 3.167
Authors: G Schleiermacher; J Michon; I Huon; C Dubois d'Enghien; J Klijanienko; H Brisse; A Ribeiro; V Mosseri; H Rubie; C Munzer; C Thomas; D Valteau-Couanet; A Auvrignon; D Plantaz; O Delattre; J Couturier Journal: Br J Cancer Date: 2007-06-19 Impact factor: 7.640
Authors: Balakrishna Koneru; Gonzalo Lopez; Ahsan Farooqi; Karina L Conkrite; Thinh H Nguyen; Shawn J Macha; Apexa Modi; Jo Lynne Rokita; Eduardo Urias; Ashly Hindle; Heather Davidson; Kristyn Mccoy; Jonas Nance; Vanda Yazdani; Meredith S Irwin; Shengping Yang; David A Wheeler; John M Maris; Sharon J Diskin; C Patrick Reynolds Journal: Cancer Res Date: 2020-04-14 Impact factor: 12.701
Authors: Jorge Delgado; Diego Jaramillo; Nancy A Chauvin; Michelle Guo; Mackenzie S Stratton; Hannah E Sweeney; Christian A Barrera; Sogol Mostoufi-Moab Journal: Pediatr Radiol Date: 2019-05-04
Authors: Luis Martí-Bonmatí; Ángel Alberich-Bayarri; Ruth Ladenstein; Ignacio Blanquer; J Damian Segrelles; Leonor Cerdá-Alberich; Polyxeni Gkontra; Barbara Hero; J M García-Aznar; Daniel Keim; Wolfgang Jentner; Karine Seymour; Ana Jiménez-Pastor; Ismael González-Valverde; Blanca Martínez de Las Heras; Samira Essiaf; Dawn Walker; Michel Rochette; Marian Bubak; Jordi Mestres; Marco Viceconti; Gracia Martí-Besa; Adela Cañete; Paul Richmond; Kenneth Y Wertheim; Tomasz Gubala; Marek Kasztelnik; Jan Meizner; Piotr Nowakowski; Salvador Gilpérez; Amelia Suárez; Mario Aznar; Giuliana Restante; Emanuele Neri Journal: Eur Radiol Exp Date: 2020-04-03